Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on VIR stock, giving a Buy rating on May 22.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Roanna Ruiz’s rating is based on Vir Biotechnology’s potential to achieve significant efficacy and safety improvements with its VIR-5500 program. Despite the competition from JNJ’s pasritamig, which has shown a strong safety profile, Ruiz believes that the market for metastatic castration-resistant prostate cancer (mCRPC) is large enough to accommodate multiple T-Cell Engager (TCE) assets. Vir’s ability to dose escalate for enhanced efficacy while maintaining a favorable safety profile is a key factor in her positive outlook.
Moreover, while pasritamig presents a challenge with its convenient dosing schedule and safety, its efficacy appears modest, which could allow VIR-5500 to capture a significant market share if it can demonstrate superior results in upcoming data releases. Ruiz expects that the continued optimization of VIR-5500’s dosing regimen and the potential for improved efficacy will attract investor attention, supporting her Buy rating on the stock.
In another report released on May 22, Needham also maintained a Buy rating on the stock with a $14.00 price target.
VIR’s price has also changed moderately for the past six months – from $8.150 to $5.070, which is a -37.79% drop .